Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance

Cell

Volumn 164, Issue 1-2, 2016, Pages 293-309

  Marcotte, Richard ^a,g,h   Sayad, Azin ^a,g   Brown, Kevin R ^b   Sanchez Garcia, Felix ^c   Reimand, Jüri ^b,g   Haider, Maliha ^a   Virtanen, Carl ^a   Bradner, James E ^d   Bader, Gary D ^b   Mills, Gordon B ^e   Pe'Er, Dana ^c   Moffat, Jason ^b   Neel, Benjamin G ^a,f  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^h NATIONAL RESEARCH COUNCIL CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BROMODOMAIN INHIBITOR; SHORT HAIRPIN RNA; BRD4 PROTEIN, HUMAN; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ALGORITHM; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GENETICS; CANCER RESISTANCE; DRUG SENSITIVITY; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC SCREENING; GENOMICS; HUMAN; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; TRANSCRIPTOMICS; BREAST NEOPLASMS; CLUSTER ANALYSIS; DRUG RESISTANCE; GENE DOSAGE; GENETICS; GENOME-WIDE ASSOCIATION STUDY; PATHOLOGY; STATISTICAL MODEL; TUMOR CELL LINE;

ALGORITHMS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENE DOSAGE; GENE EXPRESSION PROFILING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LINEAR MODELS; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; TRANSCRIPTION FACTORS;

EID: 84954290430     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2015.11.062     Document Type: Article

References (68)

1. S. Banerji, K. Cibulskis, C. Rangel-Escareno, K.K. Brown, S.L. Carter, A.M. Frederick, M.S. Lawrence, A.Y. Sivachenko, C. Sougnez, L. Zou, and et al. Sequence analysis of mutations and translocations across breast cancer subtypes Nature 486 2012 405 409
2. D.A. Barbie, P. Tamayo, J.S. Boehm, S.Y. Kim, S.E. Moody, I.F. Dunn, A.C. Schinzel, P. Sandy, E. Meylan, C. Scholl, and et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 Nature 462 2009 108 112
3. J.M. Bosher, T. Williams, and H.C. Hurst The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma Proc. Natl. Acad. Sci. USA 92 1995 744 747
4. G. Buchwalter, M.M. Hickey, A. Cromer, L.M. Selfors, R.N. Gunawardane, J. Frishman, R. Jeselsohn, E. Lim, D. Chi, X. Fu, and et al. PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells Cancer Cell 23 2013 753 767
5. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
6. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
7. H.W. Cheung, G.S. Cowley, B.A. Weir, J.S. Boehm, S. Rusin, J.A. Scott, A. East, L.D. Ali, P.H. Lizotte, T.C. Wong, and et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer Proc. Natl. Acad. Sci. USA 108 2011 12372 12377
8. D. Cortez, Y. Wang, J. Qin, and S.J. Elledge Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks Science 286 1999 1162 1166
9. C.J. Creighton, X. Li, M. Landis, J.M. Dixon, V.M. Neumeister, A. Sjolund, D.L. Rimm, H. Wong, A. Rodriguez, J.I. Herschkowitz, and et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc. Natl. Acad. Sci. USA 106 2009 13820 13825
10. C. Curtis, S.P. Shah, S.F. Chin, G. Turashvili, O.M. Rueda, M.J. Dunning, D. Speed, A.G. Lynch, S. Samarajiwa, Y. Yuan, et al. METABRIC Group The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups Nature 486 2012 346 352
11. A. Daemen, O.L. Griffith, L.M. Heiser, N.J. Wang, O.M. Enache, Z. Sanborn, F. Pepin, S. Durinck, J.E. Korkola, M. Griffith, and et al. Modeling precision treatment of breast cancer Genome Biol. 14 2013 R110
12. C.V. Dang MYC on the path to cancer Cell 149 2012 22 35
13. T. Davoli, A.W. Xu, K.E. Mengwasser, L.M. Sack, J.C. Yoon, P.J. Park, and S.J. Elledge Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome Cell 155 2013 948 962
14. S. Dhillon Palbociclib: first global approval Drugs 75 2015 543 551
15. Q.P. Dou, and J.A. Zonder Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system Curr. Cancer Drug Targets 14 2014 517 536
16. H. Dvinge, A. Git, S. Gräf, M. Salmon-Divon, C. Curtis, A. Sottoriva, Y. Zhao, M. Hirst, J. Armisen, E.A. Miska, and et al. The shaping and functional consequences of the microRNA landscape in breast cancer Nature 497 2013 378 382
17. M.J. Ellis, L. Ding, D. Shen, J. Luo, V.J. Suman, J.W. Wallis, B.A. Van Tine, J. Hoog, R.J. Goiffon, T.C. Goldstein, and et al. Whole-genome analysis informs breast cancer response to aromatase inhibition Nature 486 2012 353 360
18. P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W.B. Smith, O. Fedorov, E.M. Morse, T. Keates, T.T. Hickman, I. Felletar, and et al. Selective inhibition of BET bromodomains Nature 468 2010 1067 1073
19. K. Flick, and P. Kaiser Set them free: F-box protein exchange by Cand1 Cell Res. 23 2013 870 871
20. C.A. French, I. Miyoshi, I. Kubonishi, H.E. Grier, A.R. Perez-Atayde, and J.A. Fletcher BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma Cancer Res. 63 2003 304 307
21. C. Furne, J. Ricard, J.R. Cabrera, L. Pays, J.R. Bethea, P. Mehlen, and D.J. Liebl EphrinB3 is an anti-apoptotic ligand that inhibits the dependence receptor functions of EphA4 receptors during adult neurogenesis Biochim. Biophys. Acta 1793 2009 231 238
22. M. Gatei, S.P. Scott, I. Filippovitch, N. Soronika, M.F. Lavin, B. Weber, and K.K. Khanna Role for ATM in DNA damage-induced phosphorylation of BRCA1 Cancer Res. 60 2000 3299 3304
23. M. Griffith, O.L. Griffith, A.C. Coffman, J.V. Weible, J.F. McMichael, N.C. Spies, J. Koval, I. Das, M.B. Callaway, J.M. Eldred, and et al. DGIdb: mining the druggable genome Nat. Methods 10 2013 1209 1210
24. W. Guo, Z. Keckesova, J.L. Donaher, T. Shibue, V. Tischler, F. Reinhardt, S. Itzkovitz, A. Noske, U. Zürrer-Härdi, G. Bell, and et al. Slug and Sox9 cooperatively determine the mammary stem cell state Cell 148 2012 1015 1028
25. Y. Guo, F. Chinyengetere, A.V. Dolinko, A. Lopez-Aguiar, Y. Lu, F. Galimberti, T. Ma, Q. Feng, D. Sekula, S.J. Freemantle, and et al. Evidence for the ubiquitin protease UBP43 as an antineoplastic target Mol. Cancer Ther. 11 2012 1968 1977
26. T. Hart, K.R. Brown, F. Sircoulomb, R. Rottapel, and J. Moffat Measuring error rates in genomic perturbation screens: gold standards for human functional genomics Mol. Syst. Biol. 10 2014 733
27. B.T. Hennessy, A.M. Gonzalez-Angulo, K. Stemke-Hale, M.Z. Gilcrease, S. Krishnamurthy, J.S. Lee, J. Fridlyand, A. Sahin, R. Agarwal, C. Joy, and et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics Cancer Res. 69 2009 4116 4124
28. A. Hollestelle, J.H. Nagel, M. Smid, S. Lam, F. Elstrodt, M. Wasielewski, S.S. Ng, P.J. French, J.K. Peeters, M.J. Rozendaal, and et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines Breast Cancer Res. Treat. 121 2010 53 64
29. T.Y. Hsu, L.M. Simon, N.J. Neill, R. Marcotte, A. Sayad, C.S. Bland, G.V. Echeverria, T. Sun, S.J. Kurley, S. Tyagi, and et al. The spliceosome is a therapeutic vulnerability in MYC-driven cancer Nature 525 2015 384 388
30. V.S. Jamdade, N. Sethi, N.A. Mundhe, P. Kumar, M. Lahkar, and N. Sinha Therapeutic targets of triple-negative breast cancer: a review Br. J. Pharmacol. 172 2015 4228 4237
31. J. Kao, K. Salari, M. Bocanegra, Y.L. Choi, L. Girard, J. Gandhi, K.A. Kwei, T. Hernandez-Boussard, P. Wang, A.F. Gazdar, and et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery PLoS ONE 4 2009 e6146
32. J.H. Kim, N.E. Hubbard, V. Ziboh, and K.L. Erickson Attenuation of breast tumor cell growth by conjugated linoleic acid via inhibition of 5-lipoxygenase activating protein Biochim. Biophys. Acta 1736 2005 244 250
33. R. König, C.Y. Chiang, B.P. Tu, S.F. Yan, P.D. DeJesus, A. Romero, T. Bergauer, A. Orth, U. Krueger, Y. Zhou, and S.K. Chanda A probability-based approach for the analysis of large-scale RNAi screens Nat. Methods 4 2007 847 849
34. B.D. Lehmann, J.A. Bauer, X. Chen, M.E. Sanders, A.B. Chakravarthy, Y. Shyr, and J.A. Pietenpol Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J. Clin. Invest. 121 2011 2750 2767
35. E. Lim, D. Wu, B. Pal, T. Bouras, M.L. Asselin-Labat, F. Vaillant, H. Yagita, G.J. Lindeman, G.K. Smyth, and J.E. Visvader Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways Breast Cancer Res. 12 2010 R21
36. M. Lupien, J. Eeckhoute, C.A. Meyer, Q. Wang, Y. Zhang, W. Li, J.S. Carroll, X.S. Liu, and M. Brown FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription Cell 132 2008 958 970
37. V. Maire, F. Némati, M. Richardson, A. Vincent-Salomon, B. Tesson, G. Rigaill, E. Gravier, B. Marty-Prouvost, L. De Koning, G. Lang, and et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer Cancer Res. 73 2013 813 823
38. R. Marcotte, K.R. Brown, F. Suarez, A. Sayad, K. Karamboulas, P.M. Krzyzanowski, F. Sircoulomb, M. Medrano, Y. Fedyshyn, J.L. Koh, and et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells Cancer Discov. 2 2012 172 189
39. T. Muranen, L.M. Selfors, D.T. Worster, M.P. Iwanicki, L. Song, F.C. Morales, S. Gao, G.B. Mills, and J.S. Brugge Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells Cancer Cell 21 2012 227 239
40. M.G. Netea, T. Azam, G. Ferwerda, S.E. Girardin, M. Walsh, J.S. Park, E. Abraham, J.M. Kim, D.Y. Yoon, C.A. Dinarello, and S.H. Kim IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism Proc. Natl. Acad. Sci. USA 102 2005 16309 16314
41. R.M. Neve, K. Chin, J. Fridlyand, J. Yeh, F.L. Baehner, T. Fevr, L. Clark, N. Bayani, J.P. Coppe, F. Tong, and et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Cancer Cell 10 2006 515 527
42. D. Nijhawan, T.I. Zack, Y. Ren, M.R. Strickland, R. Lamothe, S.E. Schumacher, A. Tsherniak, H.C. Besche, J. Rosenbluh, S. Shehata, and et al. Cancer vulnerabilities unveiled by genomic loss Cell 150 2012 842 854
43. C. O'Callaghan, L.J. Fanning, and O.P. Barry p38δ MAPK: Emerging Roles of a Neglected Isoform Int. J. Cell Biol. 2014 2014 272689
44. D. Pan, and X. Lin Epithelial growth factor receptor-activated nuclear factor kappaB signaling and its role in epithelial growth factor receptor-associated tumors Cancer J. 19 2013 461 467
45. G.M. Pao, R. Janknecht, H. Ruffner, T. Hunter, and I.M. Verma CBP/p300 interact with and function as transcriptional coactivators of BRCA1 Proc. Natl. Acad. Sci. USA 97 2000 1020 1025
46. J.S. Parker, M. Mullins, M.C. Cheang, S. Leung, D. Voduc, T. Vickery, S. Davies, C. Fauron, X. He, Z. Hu, and et al. Supervised risk predictor of breast cancer based on intrinsic subtypes J. Clin. Oncol. 27 2009 1160 1167
47. C.M. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, and et al. Molecular portraits of human breast tumours Nature 406 2000 747 752
48. F. Petrocca, G. Altschuler, S.M. Tan, M.L. Mendillo, H. Yan, D.J. Jerry, A.L. Kung, W. Hide, T.A. Ince, and J. Lieberman A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells Cancer Cell 24 2013 182 196
49. A. Prat, J.S. Parker, O. Karginova, C. Fan, C. Livasy, J.I. Herschkowitz, X. He, and C.M. Perou Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer Breast Cancer Res. 12 2010 R68
50. M. Rahmani, M.M. Aust, E. Attkisson, D.C. Williams Jr., A. Ferreira-Gonzalez, and S. Grant Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism Cancer Res. 73 2013 1340 1351
51. M. Riaz, M.T. van Jaarsveld, A. Hollestelle, W.J. Prager-van der Smissen, A.A. Heine, A.W. Boersma, J. Liu, J. Helmijr, B. Ozturk, M. Smid, and et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs Breast Cancer Res. 15 2013 R33
52. F. Sanchez-Garcia, P. Villagrasa, J. Matsui, D. Kotliar, V. Castro, U.D. Akavia, B.J. Chen, L. Saucedo-Cuevas, R. Rodriguez Barrueco, D. Llobet-Navas, and et al. Integration of genomic data enables selective discovery of breast cancer drivers Cell 159 2014 1461 1475
53. S.P. Shah, A. Roth, R. Goya, A. Oloumi, G. Ha, Y. Zhao, G. Turashvili, J. Ding, K. Tse, G. Haffari, and et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers Nature 486 2012 395 399
54. D.D. Shao, A. Tsherniak, S. Gopal, B.A. Weir, P. Tamayo, N. Stransky, S.E. Schumacher, T.I. Zack, R. Beroukhim, L.A. Garraway, and et al. ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens Genome Res. 23 2013 665 678
55. J. Shi, and C.R. Vakoc The mechanisms behind the therapeutic activity of BET bromodomain inhibition Mol. Cell 54 2014 728 736
56. N.L. Solimini, Q. Xu, C.H. Mermel, A.C. Liang, M.R. Schlabach, J. Luo, A.E. Burrows, A.N. Anselmo, A.L. Bredemeyer, M.Z. Li, and et al. Recurrent hemizygous deletions in cancers may optimize proliferative potential Science 337 2012 104 109
57. T. Sørlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, and et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc. Natl. Acad. Sci. USA 98 2001 10869 10874
58. V. Stagni, I. Manni, V. Oropallo, M. Mottolese, A. Di Benedetto, G. Piaggio, R. Falcioni, D. Giaccari, S. Di Carlo, F. Sperati, and et al. ATM kinase sustains HER2 tumorigenicity in breast cancer Nat. Commun. 6 2015 6886
59. P.J. Stephens, P.S. Tarpey, H. Davies, P. Van Loo, C. Greenman, D.C. Wedge, S. Nik-Zainal, S. Martin, I. Varela, G.R. Bignell, et al. Oslo Breast Cancer Consortium (OSBREAC) The landscape of cancer genes and mutational processes in breast cancer Nature 486 2012 400 404
60. E.E. Stratikopoulos, M. Dendy, M. Szabolcs, A.J. Khaykin, C. Lefebvre, M.M. Zhou, and R. Parsons Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy Cancer Cell 27 2015 837 851
61. M. Takemoto, T. Fukuda, R. Sonoda, F. Murakami, H. Tanaka, and N. Yamamoto Ephrin-B3-EphA4 interactions regulate the growth of specific thalamocortical axon populations in vitro Eur. J. Neurosci. 16 2002 1168 1172
62. R. Tibes, Y. Qiu, Y. Lu, B. Hennessy, M. Andreeff, G.B. Mills, and S.M. Kornblau Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells Mol. Cancer Ther. 5 2006 2512 2521
63. L.A. Timmerman, T. Holton, M. Yuneva, R.J. Louie, M. Padró, A. Daemen, M. Hu, D.A. Chan, S.P. Ethier, L.J. van 't Veer, and et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target Cancer Cell 24 2013 450 465
64. C.A. Worby, and J.E. Dixon Pten Annu. Rev. Biochem. 83 2014 641 669
65. N.G. Yousif, F.G. Al-Amran, N. Hadi, J. Lee, and J. Adrienne Expression of IL-32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer Cytokine 61 2013 223 227
66. F. Yu, J. Li, H. Chen, J. Fu, S. Ray, S. Huang, H. Zheng, and W. Ai Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion Oncogene 30 2011 2161 2172
67. L. Zender, W. Xue, J. Zuber, C.P. Semighini, A. Krasnitz, B. Ma, P. Zender, S. Kubicka, J.M. Luk, P. Schirmacher, and et al. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer Cell 135 2008 852 864
68. L. Zhang, Y. Zhang, A. Mehta, M. Boufraqech, S. Davis, J. Wang, Z. Tian, Z. Yu, M.B. Boxer, J.A. Kiefer, and et al. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer Oncotarget 6 2015 9073 9085